

Repros Therapeutics Inc. Fundamental Company Report Including Financial, SWOT, Competitors and Industry Analysis

https://marketpublishers.com/r/R78DA82086CBEN.html

Date: May 2025

Pages: 50

Price: US\$ 499.00 (Single User License)

ID: R78DA82086CBEN

Abstracts

Repros Therapeutics Inc. Fundamental Company Report provides a complete overview of the company's affairs. All available data is presented in a comprehensive and easily accessed format. The report includes financial and SWOT information, industry analysis, opinions, estimates, plus annual and quarterly forecasts made by stock market experts. The report also enables direct comparison to be made between Repros Therapeutics Inc. and its competitors. This provides our Clients with a clear understanding of Repros Therapeutics Inc. position in the Pharmaceuticals and Biotechnology Industry.

The report contains detailed information about Repros Therapeutics Inc. that gives an unrivalled in-depth knowledge about internal business-environment of the company: data about the owners, senior executives, locations, subsidiaries, markets, products, and company history.

Another part of the report is a SWOT-analysis carried out for Repros Therapeutics Inc.. It involves specifying the objective of the company's business and identifies the different factors that are favorable and unfavorable to achieving that objective. SWOT-analysis helps to understand company's strengths, weaknesses, opportunities, and possible threats against it.

The Repros Therapeutics Inc. financial analysis covers the income statement and ratio trend-charts with balance sheets and cash flows presented on an annual and quarterly basis. The report outlines the main financial ratios



pertaining to profitability, margin analysis, asset turnover, credit ratios, and company's long-term solvency. This sort of company's information will assist and strengthen your company's decision-making processes.

In the part that describes Repros Therapeutics Inc. competitors and the industry in whole, the information about company's financial ratios is compared to those of its competitors and to the industry. The unique analysis of the market and company's competitors along with detailed information about the internal and external factors affecting the relevant industry will help to manage your business environment. Your company's business and sales activities will be boosted by gaining an insight into your competitors' businesses.

Also the report provides relevant news, an analysis of PR-activity, and stock price movements. The latter are correlated with pertinent news and press releases, and annual and quarterly forecasts are given by a variety of experts and market research firms. Such information creates your awareness about principal trends of Repros Therapeutics Inc. business.

About Repros Therapeutics Inc.

Repros Therapeutics, Inc., a development stage biopharmaceutical company, focuses on the development of oral small molecule drugs for unmet medical needs.

Products

Androxal

The company's primary product, Androxal (the trans isomer of clomiphene), is a single isomer of clomiphene citrate and is an orally active proprietary small molecule compound. The company is developing Androxal for men of reproductive age with low testosterone levels who want to improve or maintain their fertility and/or sperm function while being treated for low testosterone. In addition, the company submitted a new investigational new drug application (IND) to the Division of Metabolic and Endocrine Products, (DMEP), for the investigation of Androxal as a treatment for type 2 diabetes. The company has a supply agreement with Diagnostic Chemical Limited, doing business as BioVectra, for the supply of the bulk active pharmaceutical ingredient used in Androxal.



Proellex

Proellex, its product candidate for female reproductive health, is a new chemical entity that acts as a selective blocker of the progesterone receptor and is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis. The company licensed rights to Proellex from the National Institutes of Health (NIH), under worldwide license in the field of treatment of human endocrinologic pathologies or conditions in steroid sensitive tissues.

Other Products

The company also involves in out-licensing of its phentolamine-based product candidates, including VASOMAX, which is approved for the treatment of male erectile dysfunction under the brand name, Z-Max. VASOMAX is on partial clinical hold in the U.S.

Competition

The company's main competitors for the treatment of uterine fibroids and endometriosis are GnRH agonists, primarily Lupron.

History

Repros Therapeutics, Inc. was founded in 1987.

The above Company Fundamental Report is a half-ready report and contents are subject to change.

It means that we have all necessary data in our database to prepare the report but need **2-3 days** to complete it. During this time we are also updating the report with respect to the current moment. So, you can get all the most recent data available for the same price. Please note that preparation of additional types of analyses requires extra time.



Contents

RESEARCH METHODOLOGY

DISCLAIMER

1. REPROS THERAPEUTICS INC. COMPANY PROFILE

- 1.1. Key facts
- 1.2. Financial Performance
- 1.3. Key Executives
- 1.4. Ownership and Major Holders
- 1.5. Company History

2. REPROS THERAPEUTICS INC. BUSINESS OVERVIEW

- 2.1. Business Description
- 2.2. Major Products and Services
- 2.3. Markets and Sales Activities
- 2.4. Locations, Subsidiaries, Operating Units

3. REPROS THERAPEUTICS INC. SWOT ANALYSIS

- 3.1. Overview
- 3.2. Strengths
- 3.3. Weaknesses
- 3.4. Opportunities
- 3.5. Threats

4. REPROS THERAPEUTICS INC. FINANCIAL ANALYSIS

- 4.1. Financial Statements
- 4.1.1. Income Statement
- 4.1.2. Balance Sheet
- 4.1.3. Cash Flow
- 4.2. Financial Ratios
- 4.2.1. Profitability
- 4.2.2. Margin Analysis



- 4.2.3. Asset Turnover
- 4.2.4. Credit Ratios
- 4.2.5. Long-Term Solvency
- 4.2.6. Growth Over Prior Year
- 4.2.7. Financial Ratios Charts
- 4.3. Stock Market Snapshot

5. REPROS THERAPEUTICS INC. COMPETITORS AND INDUSTRY ANALYSIS

- 5.1. Repros Therapeutics Inc. Direct Competitors
- 5.2. Comparison of Repros Therapeutics Inc. and Direct Competitors Financial Ratios
- 5.3. Comparison of Repros Therapeutics Inc. and Direct Competitors Stock Charts
- 5.4. Repros Therapeutics Inc. Industry Analysis
- 5.4.1. Pharmaceuticals and Biotechnology Industry Snapshot
 - 5.4.2. Repros Therapeutics Inc. Industry Position Analysis

6. REPROS THERAPEUTICS INC. NEWS & EVENTS

- 6.1. News & PR Activity Analysis
- 6.2. IR Corporate News
- 6.3. Marketing News
- 6.4. Corporate Events

7. REPROS THERAPEUTICS INC. EXPERTS REVIEW1

- 7.1. Experts Consensus
- 7.2. Experts Revisions

8. REPROS THERAPEUTICS INC. ENHANCED SWOT ANALYSIS²

9. UNITED STATES PESTEL ANALYSIS²

- 9.1. Political Factors
- 9.2. Economic Factors
- 9.3. Social Factors
- 9.4. Technological Factors
- 9.5. Environmental Factors
- 9.6. Legal Factors



10. REPROS THERAPEUTICS INC. IFE, EFE, IE MATRICES²

- 10.1. Internal Factor Evaluation Matrix
- 10.2. External Factor Evaluation Matrix
- 10.3. Internal External Matrix

11. REPROS THERAPEUTICS INC. PORTER FIVE FORCES ANALYSIS²

12. REPROS THERAPEUTICS INC. VRIO ANALYSIS²

APPENDIX: RATIO DEFINITIONS

LIST OF FIGURES

Repros Therapeutics Inc. Annual Revenues in Comparison with Cost of Goods Sold

and Gross Profit

Profit Margin Chart

Operating Margin Chart

Return on Equity (ROE) Chart

Return on Assets (ROA) Chart

Debt to Equity Chart

Current Ratio Chart

Repros Therapeutics Inc. 1-year Stock Charts

Repros Therapeutics Inc. 5-year Stock Charts

Repros Therapeutics Inc. vs. Main Indexes 1-year Stock Chart

Repros Therapeutics Inc. vs. Direct Competitors 1-year Stock Charts

Repros Therapeutics Inc. Article Density Chart

The complete financial data is available for publicly traded companies.

^{1 –} Data availability depends on company's security policy.

^{2 –} These sections are available only when you purchase a report with appropriate additional types of analyses.



List Of Tables

LIST OF TABLES

Repros Therapeutics Inc. Key Facts

Profitability

Management Effectiveness

Income Statement Key Figures

Balance Sheet Key Figures

Cash Flow Statement Key Figures

Financial Performance Abbreviation Guide

Repros Therapeutics Inc. Key Executives

Repros Therapeutics Inc. Major Shareholders

Repros Therapeutics Inc. History

Repros Therapeutics Inc. Products

Revenues by Segment

Revenues by Region

Repros Therapeutics Inc. Offices and Representations

Repros Therapeutics Inc. SWOT Analysis

Yearly Income Statement Including Trends

Income Statement Latest 4 Quarters Including Trends

Yearly Balance Sheet Including Trends

Balance Sheet Latest 4 Quarters Including Trends

Yearly Cash Flow Including Trends

Cash Flow Latest 4 Quarters Including Trends

Repros Therapeutics Inc. Profitability Ratios

Margin Analysis Ratios

Asset Turnover Ratios

Credit Ratios

Long-Term Solvency Ratios

Financial Ratios Growth Over Prior Year

Repros Therapeutics Inc. Capital Market Snapshot

Repros Therapeutics Inc. Direct Competitors Key Facts

Direct Competitors Profitability Ratios

Direct Competitors Margin Analysis Ratios

Direct Competitors Asset Turnover Ratios

Direct Competitors Credit Ratios

Direct Competitors Long-Term Solvency Ratios

Pharmaceuticals and Biotechnology Industry Statistics



Repros Therapeutics Inc. Industry Position

Company vs. Industry Income Statement Analysis

Company vs. Industry Balance Sheet Analysis

Company vs. Industry Cash Flow Analysis

Company vs. Industry Ratios Comparison

Repros Therapeutics Inc. Consensus Recommendations¹

Analyst Recommendation Summary¹

Price Target Summary¹

Experts Recommendation Trends¹

Revenue Estimates Analysis¹

Earnings Estimates Analysis¹

Historical Surprises¹

Revenue Estimates Trend¹

Earnings Estimates Trend¹

Revenue Revisions¹



ANALYSIS FEATURES

SWOT Analysis

SWOT, which stands for Strengths, Weaknesses, Opportunities and Threats, is an analytical framework that identifies the internal and external factors that are favorable and unfavorable for a company.

Enhanced SWOT Analysis

Enhanced SWOT is a 3×3 grid that arranges strengths, weaknesses, opportunities and threats into one scheme:

How to use the strengths to take advantage of the opportunities?

How to use the strengths to reduce likelihood and impact of the threats?

How to overcome the weaknesses that obstruct taking advantage of the opportunities?

How to overcome the weaknesses that can make the threats a reality?

Upon answering these questions a company can develop a project plan to improve its business performance.

PESTEL Analysis

PESTEL (also termed as PESTLE) is an ideal tool to strategically analyze what influence different outside factors – political, economic, sociocultural, technological, environmental and legal – exert on a business to later chart its long term targets.

Being part of the external analysis when carrying out a strategic assessment or performing a market study, PESTEL gives an overview of diverse macro-environmental factors that any company should thoughtfully consider. By perceiving these outside environments, businesses can maximally benefit from the opportunities while minimizing the threats to the organization.



Key Factors Examined by PESTEL Analysis:

Political – What opportunities and pressures are brought by political bodies and what is the degree of public regulations' impact on the business?

Economic – What economic policies, trends and structures are expected to affect the organization, what is this influence's degree?

Sociological – What cultural and societal aspects will work upon the demand for the business's products and operations?

Technological – What impact do the technological aspects, innovations, incentives and barriers have on the organization?

Environmental – What environmental and ecological facets, both locally and farther afield, are likely to predetermine the business?

Legal – What laws and legislation will exert influence on the style the business is carried out?

IFE, EFE, IE Matrices

The Internal Factor Evaluation matrix (IFE matrix) is a strategic management tool helping audit or evaluate major weaknesses and strengths in a business's functional areas. In addition, IFE matrix serves as a basis for identifying and assessing relationships amongst those areas. The IFE matrix is utilised in strategy formulation.

The External Factor Evaluation matrix (EFE matrix) is a tool of strategic management that is typically utilised to assess current market conditions. It is an ideal instrument for visualising and prioritising the threats and opportunities a firm is facing.

The essential difference between the above mentioned matrices lies in the type of factors incorporated in the model; whilst the latter is engaged in internal factors, the former deals exceptionally with external factors – those exposed to social, political, economic, legal, etc. external forces.

Being a continuation of the EFE matrix and IFE matrix models, the Internal External matrix (IE matrix) rests upon an investigation of external and internal business factors



integrated into one suggestive model.

Porter Five Forces Analysis

The Porter's five forces analysis studies the industry of operation and helps the company find new sources of competitive advantage. The analysis surveys an industry through five major questions:

What composes a threat of substitute products and services?

Is there a threat of new competitors entering the market?

What is the intensity of competitive rivalry?

How big is the bargaining power of buyers?

How significant is the bargaining power of suppliers?

VRIO Analysis

VRIO stands for Value, Rarity, Imitability, Organization. This analysis helps to evaluate all company's resources and capabilities and bring them together into one aggregate table that includes:

Tangible resources

Financial

Physical

Technological

Organizational

Intangible resources

Human

Innovation and Creativity



Reputation

Organizational capabilities

The result of the analysis gives a clear picture of company's competitive and economic implications, answering the questions if the resources mentioned above are:

Valuable?
Rare?
Costly to imitate?
Organized properly?



I would like to order

Product name: Repros Therapeutics Inc. Fundamental Company Report Including Financial, SWOT,

Competitors and Industry Analysis

Product link: https://marketpublishers.com/r/R78DA82086CBEN.html

Price: US\$ 499.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer

Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page https://marketpublishers.com/r/R78DA82086CBEN.html